Literature DB >> 33638197

Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review.

Jack West1, Paul J Gow1,2, Adam Testro1,2, Brooke Chapman1,2, Marie Sinclair1,2.   

Abstract

Reduction in muscle mass is a highly prevalent phenomenon in cirrhosis and is now well-documented to be associated with significant morbidity and mortality. Research into muscle loss in cirrhosis remains limited by an ongoing poor understanding of its relationship with muscle function, physical activity, and aerobic capacity. Alterations in exercise physiology have been documented in studies of individuals with cirrhosis that provide important information on physical function that is not captured by simple quantification of muscle mass. Despite expert consensus recommending regular exercise in end-stage liver disease to maintain muscle mass and function, there is little evidence guiding clinicians as to which form of exercise or delivery mechanism is most effective. It also remains unproven whether any specific intervention can alter clinically relevant outcomes. This review article summarizes the available literature regarding the changes in exercise physiology observed in cirrhosis, the associated impact on physical capacity, and the results of existing trials that examine the potential benefits of exercise delivery in patients with cirrhosis, particularly pertaining to their impact on exercise physiology.
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Cirrhosis; Exercise; Frailty; Muscle; Sarcopenia

Mesh:

Year:  2021        PMID: 33638197     DOI: 10.1111/jgh.15474

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  2 in total

1.  The efficacy of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: A protocol for systematic review and meta-analysis.

Authors:  Na Wang; Wei Yao; Ruiping Ma; Fangfang Ren
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

2.  Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.

Authors:  Koji Murata; Kosuke Kaji; Norihisa Nishimura; Masahide Enomoto; Yuki Fujimoto; Soichi Takeda; Yuki Tsuji; Yukihisa Fujinaga; Hiroaki Takaya; Hideto Kawaratani; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  Int J Mol Med       Date:  2022-06-10       Impact factor: 5.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.